title: HBV-DNA suppression and disease course in HBV cirrhosis patients on long-term lamivudine therapy.
abstract: In hepatitis B virus (HBV) cirrhosis patients on long-term lamivudine (LAM), the relationships between HBV suppression, development of viral resistance and disease outcome are unclear. We analysed the dynamic of serum HBV-DNA and its relationship with the clinical course of 59 patients (52 males, mean age 51.4 +/- 8.4 years, 12 HBeAg positive and 47 HBeAg negative, and 57 genotype D and two genotype A) with cirrhosis (45 in Child-Turcotte-Pugh class A) and high levels of serum HBV-DNA (median 14.7 x 10(7) genomes/ml) treated with LAM [median (range): 44 (15-78) months]. A total of 50 patient (84.7%) achieved a virological response (serum HBV-DNA negative by PCR) during the first 6 months of therapy, and nine (13.3%) achieved a reduction in viral load of > 3 log10. Mutations in the YMDD motif of HBV polymerase were documented in 26 patients [median (range) 18: (7-42) months]. At the time of the emergence of mutants, 22 patients had HBV-DNA < 10(5) genomes/ml and normal alanine aminotransferase (ALT) levels. The appearance of virological resistance was followed by an increase of HBV-DNA to > 10(5) genomes/ml and of ALT values in 19 out of 26 patients [median (range): 8 (3-19) months]. Event-free survival was significantly longer (P = 0.001) in patients who maintained virological suppression than in those who did not have a complete virological response or suffered a breakthrough. Patients with advanced cirrhosis were more likely to develop liver failure after the emergence of YMDD mutants. The risk of development of hepatocellular carcinoma in patients with compensated cirrhosis and YMDD mutations was maintained, regardless of HBV-DNA serum levels. Profound and maintained HBV-DNA suppression correlates with a better outcome. Early identification of LAM resistance mutations allows switching to other antivirals before liver decompensation or hepatocellular carcinoma development.
authors.affiliation: Cattedra e Unità Operativa Complessa di Gastroenterologia ed Epatologia, University of Palermo, Palermo, Italy. vito.dimarco@tin.it
authors.forename: Vito
authors.initials: V
authors.lastname: Di Marco
authors.forename: Rosa
authors.initials: R
authors.lastname: Di Stefano
authors.forename: Donatella
authors.initials: D
authors.lastname: Ferraro
authors.forename: Piero Luigi
authors.initials: PL
authors.lastname: Almasio
authors.forename: Celestino
authors.initials: C
authors.lastname: Bonura
authors.forename: Maria
authors.initials: M
authors.lastname: Giglio
authors.forename: Pietro
authors.initials: P
authors.lastname: Parisi
authors.forename: Maria
authors.initials: M
authors.lastname: Cappello
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Alaimo
authors.forename: Antonio
authors.initials: A
authors.lastname: Craxì
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D015331:Cohort Studies; D004279:DNA, Viral / Q000097:blood* / Q000235:genetics; D004334:Drug Administration Schedule; D005260:Female; D006509:Hepatitis B / Q000503:physiopathology* / Q000821:virology; D006515:Hepatitis B virus / Q000235:genetics; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use*; D008103:Liver Cirrhosis / Q000503:physiopathology* / Q000821:virology; D008297:Male; D008875:Middle Aged; D009154:Mutation; D014779:Virus Replication
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D019259:Lamivudine